📰 Priority Review News
Page 22 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
January 5, 2024
/PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A...
January 3, 2024
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.
January 1, 2024
The global Small Lymphocytic Lymphoma Treatment market has significantly grown over the past few years and is expected to register rapid growth. Revenue...
January 1, 2024
New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program
December 27, 2023
Patritumab deruxtecan is under review to treat previously treated adults with locally advanced or metastatic EGFR-mutated NSCLC.
December 26, 2023
The FDA has granted Priority Review for the supplemental New Drug Application for Tarpeyo (budesonide) seeking full approval in the treatment of IgA nephropathy.
December 23, 2023
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for...
December 22, 2023
Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
December 22, 2023
(RTTNews) - Merck & Co. Inc. (MRK) and Japans Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA...
December 21, 2023
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.